Kidney Fibrosis - Pipeline Review, H2 2017

  • ID: 4412874
  • Report
  • Region: Global
  • 133 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Apollo Endosurgery Inc
  • Cellmid Ltd
  • Galectin Therapeutics Inc
  • Isarna Therapeutics GmbH
  • Redx Pharma Plc
  • MORE

Kidney Fibrosis - Pipeline Review, H2 2017

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis - Pipeline Review, H2 2017, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Kidney Fibrosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 29 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Apollo Endosurgery Inc
  • Cellmid Ltd
  • Galectin Therapeutics Inc
  • Isarna Therapeutics GmbH
  • Redx Pharma Plc
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Kidney Fibrosis - Overview

Kidney Fibrosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Kidney Fibrosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Kidney Fibrosis - Companies Involved in Therapeutics Development

AbbVie Inc

AdAlta Ltd

Angion Biomedica Corp

Apollo Endosurgery Inc

BiOrion Technologies BV

BLR Bio LLC

Cellmid Ltd

Epigen Biosciences Inc

Evotec AG

Galectin Therapeutics Inc

GenKyoTex SA

Genzyme Corp

Intercept Pharmaceuticals Inc

Isarna Therapeutics GmbH

MorphoSys AG

Pharmaxis Ltd

ProMetic Life Sciences Inc

Redx Pharma Plc

Regulus Therapeutics Inc

Sirnaomics Inc

Vascular Biogenics Ltd

Kidney Fibrosis - Drug Profiles

1D-11 - Drug Profile

AD-114 - Drug Profile

ANG-3070 - Drug Profile

ANG-3586 - Drug Profile

ANG-4021 - Drug Profile

BLR-400 - Drug Profile

BMP-7 - Drug Profile

BOT-191 - Drug Profile

CAB-102 - Drug Profile

CT-140 - Drug Profile

Drugs for Tissue Fibrosis - Drug Profile

GAL-300 - Drug Profile

Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile

GKT-136901 - Drug Profile

GRMD-02 - Drug Profile

ICG-001 - Drug Profile

INT-767 - Drug Profile

IP-9 - Drug Profile

ISTH-0047 - Drug Profile

LJ-1888 - Drug Profile

Lpathomab - Drug Profile

melittin - Drug Profile

MOR-107 - Drug Profile

MSB-003 - Drug Profile

MSB-014 - Drug Profile

P-007 - Drug Profile

PAT-1251 - Drug Profile

PAT-505 - Drug Profile

PBI-4050 - Drug Profile

PXS-4820 - Drug Profile

PXS-5033A - Drug Profile

PXS-5382A - Drug Profile

REDX-06109 - Drug Profile

RG-012 - Drug Profile

Small Molecule to Antagonize AlphaV and Beta6 for Fibrosis - Drug Profile

Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis - Drug Profile

Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis - Drug Profile

SOL-1 - Drug Profile

STP-705 - Drug Profile

Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis - Drug Profile

TEW-7197 - Drug Profile

VB-0004 - Drug Profile

VB-201 - Drug Profile

VB-703 - Drug Profile

Wnt-001 - Drug Profile

Kidney Fibrosis - Dormant Projects

Kidney Fibrosis - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Kidney Fibrosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Kidney Fibrosis - Pipeline by AbbVie Inc, H2 2017

Kidney Fibrosis - Pipeline by AdAlta Ltd, H2 2017

Kidney Fibrosis - Pipeline by Angion Biomedica Corp, H2 2017

Kidney Fibrosis - Pipeline by Apollo Endosurgery Inc, H2 2017

Kidney Fibrosis - Pipeline by BiOrion Technologies BV, H2 2017

Kidney Fibrosis - Pipeline by BLR Bio LLC, H2 2017

Kidney Fibrosis - Pipeline by Cellmid Ltd, H2 2017

Kidney Fibrosis - Pipeline by Epigen Biosciences Inc, H2 2017

Kidney Fibrosis - Pipeline by Evotec AG, H2 2017

Kidney Fibrosis - Pipeline by Galectin Therapeutics Inc, H2 2017

Kidney Fibrosis - Pipeline by GenKyoTex SA, H2 2017

Kidney Fibrosis - Pipeline by Genzyme Corp, H2 2017

Kidney Fibrosis - Pipeline by Intercept Pharmaceuticals Inc, H2 2017

Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2017

Kidney Fibrosis - Pipeline by MorphoSys AG, H2 2017

Kidney Fibrosis - Pipeline by Pharmaxis Ltd, H2 2017

Kidney Fibrosis - Pipeline by ProMetic Life Sciences Inc, H2 2017

Kidney Fibrosis - Pipeline by Redx Pharma Plc, H2 2017

Kidney Fibrosis - Pipeline by Regulus Therapeutics Inc, H2 2017

Kidney Fibrosis - Pipeline by Sirnaomics Inc, H2 2017

Kidney Fibrosis - Pipeline by Vascular Biogenics Ltd, H2 2017

Kidney Fibrosis - Dormant Projects, H2 2017

List of Figures

Number of Products under Development for Kidney Fibrosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • AdAlta Ltd
  • Angion Biomedica Corp
  • Apollo Endosurgery Inc
  • BiOrion Technologies BV
  • BLR Bio LLC
  • Cellmid Ltd
  • Epigen Biosciences Inc
  • Evotec AG
  • Galectin Therapeutics Inc
  • GenKyoTex SA
  • Genzyme Corp
  • Intercept Pharmaceuticals Inc
  • Isarna Therapeutics GmbH
  • MorphoSys AG
  • Pharmaxis Ltd
  • ProMetic Life Sciences Inc
  • Redx Pharma Plc
  • Regulus Therapeutics Inc
  • Sirnaomics Inc
  • Vascular Biogenics Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll